Staublein
Staublein v. Acadia Pharmaceuticals Inc.
Opinion
Trial Court Opinion
UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF CALIFORNIA 10 IN RE ACADIA PHARMACEUTICALS Case No.: 18-cv-01647-AJB-BGS
INC. SECURITIES LITIGATION
ORDER GRANTING DEFENDANTS’
MOTION TO DISMISS THE THIRD
AMENDED COMPLAINT WITHOUT
LEAVE TO AMEND
15 (Doc. No. 107) 16 17 Before the Court is Defendants’ motion to dismiss Plaintiff’s Third Amended Complaint (“TAC”) in this securities-fraud action. (Doc. No. 107.) Plaintiff filed an opposition, to which Defendants replied. (Doc. Nos. 108, 109.) For the reasons set forth below, the Court GRANTS Defendants’ motion to dismiss. I. BACKGROUND A. Factual Background This case is a putative class action, involving a class of individuals who acquired ACADIA securities between April 29, 2016, and July 9, 2018, and are suing Defendants— Acadia Pharmaceuticals Inc. (“Acadia”), and individuals Stephen R. Davis (“Davis”), Todd S. Young (“Young”), Srdjan Stankovic (“Stankovic”), Terrance Moore…